| 22-01-07 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 22-01-06 | Notification about results of final buy-back of shares | AQ |
| 21-12-30 | Notification about final share buy-back | AQ |
| 21-12-28 | Correction: Regarding results of a share buy-back offer | AQ |
| 21-12-28 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 2025-12-31 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 2009-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 2021-06-18 | |
Janis Buks
CHM | Chairman | - | 2022-08-31 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/4/21 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.19% | +2.67% | - | - | 148M | |
| +0.36% | +0.02% | +13.65% | +64.92% | 46.34B | |
| -1.02% | -2.67% | +38.33% | +108.43% | 37.12B | |
| -0.17% | +4.67% | +10.94% | +92.13% | 12.13B | |
| -0.84% | +1.07% | -10.12% | +16.38% | 11.7B | |
| -0.19% | -0.19% | +19.59% | +140.28% | 8.99B | |
| +0.16% | +0.71% | +26.52% | +39.83% | 7.25B | |
| +0.24% | +2.38% | +22.34% | +214.09% | 7.27B | |
| -0.06% | +1.51% | +38.94% | -16.76% | 7.13B | |
| -0.67% | +5.34% | -39.90% | +11.48% | 5.16B | |
| Average | +0.55% | +1.86% | +13.36% | +74.53% | 15.9B | |
| Weighted average by Cap. | -0.21% | +0.81% | +18.67% | +79.59% |
Employees
2,191
Sector
Pharmaceuticals
